Business Context and Reporting Period
Company: Topspin Medical, Inc. (Note: Input metadata referenced "My Size, Inc.", but the filing text identifies the registrant as Topspin Medical, Inc.)
Reporting Period: Quarter ended March 31, 2009
Status: Development Stage Company
Operations: The Company designs and develops MRI imaging devices. Operational activities were suspended in October 2008 due to financial constraints and the settlement of Series A Debentures. As of the reporting date, the Company has no revenue and is focused on seeking financing to resume operations.
Key Financial Metrics
| Metric | Q1 2009 (NIS '000s) | Q1 2008 (NIS '000s) |
|---|---|---|
| Revenue | 0 | 0 |
| Net Loss | (982) | 267 (Income) |
| Operating Loss | (751) | (6,961) |
| Cash and Cash Equivalents (End of Period) | 3,234 | 32,959 |
| Net Cash Used in Operating Activities | (1,430) | (7,850) |
| Net Cash Provided by Financing Activities | 900 | 42 |
| Accumulated Deficit | (181,423) | N/A |
| Total Liabilities | 4,571 | N/A |
Note: All figures are in thousands of New Israeli Shekels (NIS). The filing does not provide explicit USD conversions for all line items, though approximate USD equivalents are mentioned in the MD&A (e.g., Cash ~$772,000).
Material Changes vs. Prior Period
- Operational Suspension: The most significant change is the suspension of operational activities (R&D and Marketing) in October 2008. Consequently, R&D expenses dropped from 5,094 NIS in Q1 2008 to 0 in Q1 2009, and Selling/Marketing expenses dropped from 374 NIS to 0.
- General & Administrative (G&A): G&A expenses decreased by approximately 50% (from 1,493 NIS to 751 NIS) due to the termination of most employees, retaining only the finance department.
- Cash Position: Cash and cash equivalents decreased significantly from 32,959 NIS in Q1 2008 to 3,234 NIS in Q1 2009, primarily due to the cash settlement of Series A Bonds in late 2008.
- Financing: The Company raised 900 NIS in Q1 2009 via a private placement of common stock and warrants, compared to minimal financing activity in the same period of 2008.
Guidance, Outlook, Risks, and Unusual Items
- Liquidity Outlook: Management believes current cash resources are sufficient for limited activities for at least 12 months. However, the Company explicitly states it must raise additional funds to redeem long-term liabilities.
- Government Grants: Management considers it "highly probable" to receive grants of approximately 3,200 NIS from the Office of the Chief Scientist (OCS) for 2008 expenses, though these are not yet recorded as assets due to uncertainty.
- Tax Contingency: A tax provision of 1,480 NIS is recorded as a long-term liability related to the conversion of Series A Bonds. There is no assurance this amount will be required to be paid.
- Legal Proceedings: An ex-employee filed a suit for 20 NIS regarding payroll holdover; the Company rejects the claim and has not recorded a provision.
- Management Changes: Subsequent to the period end, the Chairman was appointed temporary CEO (later changed to consultant), the Director of Finance resigned, and a new Finance Manager was appointed with stock options.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the 3.2 million NIS cash balance against the 12-month budget for limited operations.
- Grant Realization: Confirm the status of the expected 3.2 million NIS grant from the Office of the Chief Scientist.
- Tax Liability: Monitor the resolution of the 1.48 million NIS tax provision related to the bond settlement.
- Capital Raising: Assess the Company's ability to secure additional funding to address long-term liabilities and resume R&D.
- Lease Obligations: Review the status of office and vehicle lease terminations and associated penalties/deposits.